CAR-T landscape is witnessing much awaited FDA approvals. Newer therapeutic applications continue to emerge at a rapid pace. Having established the scientific foundation, the question of affordability becomes the next challenge that the industry must overcome. The presentation discusses end-to-end, fully automated, closed manufacturing as the key strategy towards a more affordable CAR-T drug product. The presentation includes a discussion of the following:

Contributors to COGs including raw material and labor.
Focus on three manufacturing related contributors: facility, labor and raw material
Cost reduction approaches for manufacturing and facility solutions